Multiplikator forward rega marang pendapatan: CureVac Corp (CVAC)

CureVac N.V. (CVAC) price action is tied to the outcomes of oncology and influenza trials, with the 12.80 metric serving as the target level. The forward P/S ratio reflects the current balance of demand, helping to assess the market discount. The German mRNA pioneer is valued for its scientific authority, while strategic alliances with pharmaceutical behemoths accelerate the market launch of new drugs.

CVAC curevac.com: Rega forward marang dodolan ing interval 04.07.2022 - 17.01.2026

CureVac Pharma (CVAC) - rincian metrik lan laporan keuangan

- rega saiki lan proyeksi nilai saham:

Rega saham CureVac|CVAC - Target konsensus

- indikator kapitalisasi bursa perusahaan:

Biji pasar CureVac Pharma|CVAC - Nilai Perusahaan

- rincian valuasi buku bisnis:

Aset Bersih saben Siji Saham CureVac|CVAC - Nilai Akuntansi Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku curevac.com|CVAC - Aset Perusahaan

- indikator beban kredit lan likuiditas emiten:

- data bathi bisnis lan rasio investasi:

CVAC - Bathi perusahaan|Bathi mangsa ngarep CureVac N.V.|CVAC - Periode bali modal bisnis|Prakiraan rega marang bathi CureVac Corp|CVAC - Rasio rega marang bathi tumrap wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan CureVac Pharma|CVAC - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) CureVac|CVAC - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan curevac.com|CVAC - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep CureVac N.V.

- statistik dodolan lan pendapatan perusahaan:

CVAC - Pendapatan lan volume dodolan|Prakiraan volume dodolan CureVac|CVAC - Kapitalisasi marang pendapatan|Rasio rega marang prakiraan pendapatan CureVac Pharma

Analisis fundamental perusahaan:CureVac CVAC

Investors utilize forward multiples to verify an asset's fair value through expected cash flows. The projected price-to-sales ratio measures the company's market value relative to its forecasted sales, reflecting the valuation's sensitivity to the cost of capital. This chart's price action allows for an assessment of market optimism regarding the commercialization of vaccines with GSK and oncology therapies. The compression of this metric confirms the fundamental strengthening of CureVac N.V. (CVAC) in the eyes of the market.

Pesaing CureVac N.V. (CVAC)

Multiplikator Forward P/S GILD (Gilead Sciences)|CDTX - Multiplikator forward rega marang pendapatan|NVAX: Multiplikator forward rega marang pendapatan|VALN - Multiplikator Forward P/S|Vir Biotechnology, Inc. (VIR) - Rasio rega marang prakiraan pendapatan|siga.com - Rega forward marang dodolan|EBS (Emergent BioSolutions Inc.) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Atea Pharma AVIR|Multiplikator forward rega marang pendapatan IVVD (Invivyd, Inc.)|Rasio rega marang prakiraan pendapatan ENTA (Enanta Pharmaceuticals, Inc)|Multiplikator Forward P/S INO (Inovio Pharmaceuticals)|Multiplikator Forward P/S hillevax.com HLVX|Kalaris Therapeutics - Multiplikator Forward P/S|Dyadic International (DYAI) - Multiplikator forward rega marang pendapatan|NNVC (nanoviricides.com) - Multiplikator forward rega marang pendapatan|Talphera Corporation - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Cocrystal Pharma, Inc.|Kapitalisasi marang prakiraan pendapatan TRAW (Traws Therapeutics)|Multiplikator forward rega marang pendapatan DWTX (Dogwood Therapeutics, Inc.)|Rasio kapitalisasi marang dodolan sing dikarepake Qualigen Therapeutics Inc|AlloVir - Multiplikator forward rega marang pendapatan|VBI Vaccines, Inc. - Rasio rega marang prakiraan pendapatan|VIRI: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Vaxart, Inc. VXRT